The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Research on IL-17 Cytokine May Lead to Novel Therapies for RA

Research on IL-17 Cytokine May Lead to Novel Therapies for RA

October 1, 2010 • By From the College

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Research in the laboratory of John D. Mountz, MD, PhD, is opening up a whole new field of study in rheumatoid arthritis (RA).

You Might Also Like
  • Naturally Occurring Antibodies May Lead to New RA Therapies
  • Research Offers Hope of New Therapies to Prevent Bone Loss and Destruction
  • Rethink Rheumatoid Arthritis Research
Explore This Issue
October 2010
Also By This Author
  • Patient Fact Sheet: Rheumatoid Arthritis

Using funds from an ACR Research and Education Foundation (REF) Within our Reach: Finding a Cure for Rheumatoid Arthritis research grant, Dr. Mountz’s lab at the University of Alabama at Birmingham is investigating the pathways through which the interleukin (IL)-17 cytokine acts on B cells. One study looked at mice that developed spontaneous germinal centers in their spleens.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“What is interesting about these mice is that the antibodies are very pathogenic. Autoantibodies from these mice can transfer arthritis,” Dr. Mountz said. “The mechanism underlying the germinal center response is particularly applicable to understanding rheumatoid arthritis.”

The study’s goal was to determine the mechanism that was causing pathogenic, arthritis-inducing autoantibodies.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
Dr. Mountz (foreground) and colleagues in the University of Alabama research laboratory.
Dr. Mountz (foreground) and colleagues in the University of Alabama research laboratory.

“There were elevated cytokines in these mice—one of the most elevated was IL-17, which was both satisfying and puzzling. [It was] satisfying because we knew it was one of the key cytokines elevated in rheumatoid arthritis. [It was] puzzling because, up to that time, IL-17 had not been reported to play a major role in the production of pathogenic autoantibodies,” Dr. Mountz said.

“We found that the IL-17 receptor was on B cells—no one had appreciated that before,” he continued. “We had known it was in other places, such as on neutrophils and synovial fibroblasts.”

Dr. Mountz’s focus has since turned to finding out how IL-17 acts on B cells, with the hopes of finding a novel target for treating RA. Novel therapies may inhibit IL-17, for example. Dr. Mountz compared it to anti–tumor necrosis factor–a therapy, which works for many arthritis patients but not all.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“This information will refocus clinicians and researchers on these antibodies. We have known that they are a factor, but where are they made? How are they made? These are very important questions, and this is a new mechanism for how it might work—its ability to drive B cell autoantibody production,” Dr. Mountz said.

“When we made the discovery in this mouse, it was so new I couldn’t get funding for it,” he noted. “It took the visionary group of people at REF’s Within Our Reach program to put faith in this, and the direction of my whole laboratory has changed. I think we have come very far with our findings, and we have begun to understand the new role of a pathogenic cytokine in rheumatoid arthritis.”

Support RA Research

To make a pledge or one-time donation to the REF for the Within Our Reach: Finding a Cure for Rheumatoid Arthritis campaign, visit www.rheumatology.org/REF. For more information about the Within Our Reach campaign, and to read about the grant projects, visit www.WithinOurReach.info.

Pages: 1 2 | Multi-Page

Filed Under: Conditions, From the College, Profiles, Rheumatoid Arthritis Tagged With: Basic research, IL-17 Cytokine, Interleukin, RA, REF News, Rheumatoid arthritis, therapy, TreatmentIssue: October 2010

You Might Also Like:
  • Naturally Occurring Antibodies May Lead to New RA Therapies
  • Research Offers Hope of New Therapies to Prevent Bone Loss and Destruction
  • Rethink Rheumatoid Arthritis Research
  • Research Tracks Possible Benefit of Src-like Adaptor Protein

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.